The farm equipment giant's weaker results reflect challenging macroeconomic conditions for the agriculture industry.Deere & Company (DE 0.66%), a leading manufacturer of agricultural, construction, and forestry machinery, released its fiscal 2024 second-quarter financial results on May 16. For the period, which ended April 28, net income fell 17% year over year to $2.4 billion, while revenue dropped 12% to $15.2 billion. Despite these challenges, the company reiterated its commitment to its strategic initia ...

It's very easy to be bullish when looking at this dominant enterprise and its long-term prospects.While it might sound like a smart idea to try and find small businesses that could become tomorrow's big winners in the stock market, investors can't ignore the companies that are hiding in plain sight.Just look at Alphabet (GOOGL 1.08%) (GOOG 1.06%). The tech titan's shares have soared 190% just in the past five years, far outpacing the broader Nasdaq Composite Index. But I don't think it's done rewarding shar ...

Core Viewpoint - Cracker Barrel Old Country Store is significantly reducing its dividend by 80% to allocate funds for business improvements, leading to a sharp decline in its stock price [1][3]. Financial Performance - The company reported trailing-12-month revenue of $3.4 billion, nearing an all-time high, with comparable-restaurant sales showing modest growth in Q2 of fiscal 2024 [2]. - Despite the revenue figures, earnings per share (EPS) are currently lower than they were a decade ago, indicating underlying financial issues [2]. Dividend Policy Changes - Cracker Barrel has a history of paying quarterly dividends and special dividends, but recent earnings deterioration has led to a situation where dividend payouts exceeded earnings, prompting the drastic cut [3]. - The decision to reduce the dividend is aimed at reallocating resources to fix the business, which has not been well received by investors, resulting in a significant drop in share price [3][4]. Future Outlook - Management is optimistic about turning the business around, with capital expenditures expected to increase through fiscal 2027, aiming for approximately $400 million in adjusted EBITDA by that time [5]. - Currently, the company has an enterprise value (EV) of $1.7 billion, and if it meets its targets, it would trade at an EBITDA-to-EV ratio of four, suggesting potential upside for the stock [6].

The industrial company's stock received another update from a highly regarded analyst recently.Another day, another Wall Street analyst upgrade for 3M (MMM 0.66%) stock. This time, it's from Vertical Research analyst Jeffrey Sprague, who upgraded the stock from "hold" to "buy" and increased his price target from $92 to $140. That target implies a 33% upside over the next 12 months from the current price.Vertical Research may not be a household name among retail investors. Still, I think Sprague is one of th ...

Reddit is partnering up with OpenAI.In today's video, I discuss recent updates impacting Nvidia (NVDA -0.18%) and Reddit (RDDT 13.67%). Check out the short video to learn more, consider subscribing, and click the special offer link below.*Stock prices used were the after-market prices of May 16, 2024. The video was published on May 16, 2024. ...

How should one makes sense of the e-commerce and cloud computing behemoth?From a certain point of view, growth investors might have good reason to move on from Amazon (AMZN 0.55%) stock. Its market cap now exceeds $1.9 trillion. Since large companies face greater challenges in achieving high-percentage growth, one might achieve higher long-term returns in a smaller e-commerce stock like MercadoLibre or Sea Limited.Nonetheless, the majority of Amazon's income is from a business outside of e-commerce, and wil ...

Core Insights - CRISPR Therapeutics is gaining recognition in the gene-editing therapy sector, achieving its first regulatory approval for Casgevy, a treatment for transfusion-dependent beta-thalassemia and sickle cell disease [1][2] Group 1: Product Development and Market Position - Casgevy requires a complex administration process involving cell collection, editing, and reinsertion via stem cell transplant, which must be conducted in authorized treatment centers [2][4] - The partnership with Vertex Pharmaceuticals has been beneficial, leading to approvals in multiple regions including the U.S., Great Britain, the EU, Saudi Arabia, and Bahrain, with pending approvals in Canada and Switzerland [3][4] - The estimated target market for Casgevy includes around 35,000 eligible patients in the U.S. and Europe, and approximately 23,000 in Saudi Arabia and Bahrain [5] Group 2: Competitive Landscape and Market Potential - International markets are critical for Casgevy, especially as competing therapies like Zynteglo and Lyfgenia have already been approved in the U.S. [6] - The potential market share for Casgevy is projected to be upwards of 20%, with a treatment cost of $2.2 million per patient in the U.S., indicating a multibillion-dollar opportunity [7] Group 3: Future Growth and Pipeline - More than 25 authorized treatment centers have been activated globally, with treatments already initiated, although exact patient numbers have not been disclosed [8] - CRISPR Therapeutics and Vertex are also focusing on expanding eligibility for Casgevy to include over 100,000 additional patients who are currently ineligible [9] - The company has five non-Casgevy candidates in clinical trials targeting various diseases, with additional programs in pre-clinical development, suggesting a strong long-term growth potential [11]

One segment drives the lion's share of financial results, but there's another division that management is focused on.In the past five years, shares of Meta Platforms (META -1.73%) have climbed 149%. That's a solid return although it has been anything but a smooth ride. Shares tanked 64% in 2022 as investors became overly pessimistic about the company's prospects.Where will this "Magnificent Seven" stock be in five years? To come up with an educated guess, I think it's worthwhile to consider what could chang ...

In a shocking turn, Disney may now have a better bundle than Netflix.Netflix (NFLX -0.49%) announced a new bundle with Comcast's (CMCSA 0.31%) Peacock and Apple (AAPL 0.06%) TV+, which is the first major streaming bundle the streaming giant has been in. What makes the move interesting is that it follows a bundle between Disney (DIS 0.58%) and Warner Bros. Discovery (WBD 0.37%).Who got the best of the bundles? That's what Travis Hoium covers in this video.*Stock prices used were end-of-day prices of May 15, ...

Here's how you can profit from this game-changing technology.Just because an investment is obvious doesn't mean it's wrong. Here are three businesses that are clear leaders in the artificial intelligence (AI) market, which could eclipse $1.8 trillion by the end of the decade. That's up from roughly $280 billion today, according to Grand View Research.With so much AI-fueled growth still to come, all three of these stocks are terrific buys right now.No. 1 AI stock to buy: NvidiaAstute investors have named Nvi ...